Bi-ksikam - instructions for use, analogs, reviews and release forms (tablets 7.5 mg and 15 mg, injections in ampoules for injection in solution) for the treatment of arthrosis, arthritis, Bechterew's disease in adults, children and pregnancy

In this article, you can read the instructions for using the drug Bi-ksikam. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Bi-ksikama in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of B-ksikam in the presence of existing structural analogs.Use for the treatment of arthrosis, arthritis, Bechterew's disease, accompanied by pain syndrome, in adults, children, as well as during pregnancy and lactation.

Bi-ksikam - a non-steroidal anti-inflammatory drug (NSAID), a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2). It belongs to the class of oxyocams, it is a derivative of enolic acid. Has anti-inflammatory, analgesic and antipyretic effect. The mechanism of action is associated with a decrease in the biosynthesis of prostaglandins as a result of inhibition of the enzymatic activity of COX. At the same time, meloxicam (the active substance of Bixikam preparation) more actively affects COX-2, which plays a role in the synthesis of prostaglandins in the inflammatory focus, which reduces the risk of side effects on the upper gastrointestinal tract (GIT) and slightly affects cyclooxygenase-1 (COX-1). At the same time, meloxicam does not affect the synthesis of proteoglycan by chondrocytes of articular cartilage, does not affect the development of spontaneous arthrosis in rats and mice, which indicates its chondroynutrality.

Composition

Meloksikam + auxiliary substances.

Pharmacokinetics

After oral administration, it is well absorbed from the digestive tract.Absolute bioavailability of meloxicam is 89%. Simultaneous food intake does not alter absorption. When taking the drug inside at doses of 7.5 mg and 15 mg, the concentration of meloxicam in the blood plasma is proportional to the dose. Binding to plasma proteins is more than 99%. Meloksikam is almost completely metabolized in the liver with the formation of 4 pharmacologically inactive metabolites. Bicciks are excreted equally with feces and urine, mainly in the form of metabolites. With feces, less than 5% of the daily dose is excreted unchanged, in urine in unchanged form the drug is detected only in trace amounts.

Indications

• arthrosis, polyarthrosis;
• osteoarthritis;
• arthritis;
• rheumatoid arthritis;
• Bechterew's disease (ankylosing spondylitis).

Forms of release

Tablets 7.5 mg and 15 mg.

Solution for intramuscular injection of 15 mg in 1.5 ml (injections in ampoules for injection).

Instructions for use and dosing regimen

The drug is taken orally during meals once a day.

With rheumatoid arthritis, the recommended dose is 15 mg per day. Depending on the therapeutic effect, the dose can be reduced to 7.5 mg per day.

With osteoarthritis, the recommended dose is 7.5 mg per day. If the dose is ineffective, it can be increased to 15 mg per day.

With ankylosing spondylitis, the dose is 15 mg per day. The maximum daily dose should not exceed 15 mg.

In patients with an increased risk of side effects, as well as in patients with hemodialysis renal insufficiency, the dose should not exceed 7.5 mg per day.

Side effect

• nausea, vomiting;
• abdominal pain;
• diarrhea, constipation;
• flatulence (bloating);
• erosive and ulcerative lesions of the gastrointestinal tract;
• perforation of the stomach or intestines;
• gastrointestinal bleeding (latent or obvious);
• increased activity of hepatic enzymes;
• hepatitis (inflammation of the liver);
• colitis (inflammation of the mucous membrane of the large intestine);
• stomatitis (inflammation of the oral mucosa);
• dry mouth;
• esophagitis (inflammation of the mucosa of the esophagus);
• Hyperbilirubinemia (increased bilirubin content in the blood);
• eructation;
• tachycardia (rapid heartbeat);
• increased blood pressure (BP);
• sensation of tides;
• exacerbation of the course of bronchial asthma;
• cough;
• headache, dizziness;
• noise in ears;
• disorientation, confusion of thoughts;
• sleep disturbance, drowsiness;
• emotional lability;
• edema;
• interstitial nephritis;
• renal medullary necrosis;
• urinary tract infection;
• proteinuria, hematuria (protein, blood in the urine);
• kidney failure;
• hypercreatininaemia and / or elevated urea in the blood serum;
• conjunctivitis;
• blurred vision;
• anemia, leukopenia, thrombocytopenia;
• itching, skin rash;
• increased photosensitivity (increased sensitivity of the body to the action of ultraviolet or visible radiation);
• hives;
• anaphylactoid reactions (including anaphylactic shock;
• angioedema;
• allergic vasculitis;
• multi-form exudative erythema (including Stevens-Johnson syndrome);
• toxic epidermal necrolysis (Lyell's syndrome);
• fever.

Contraindications

• "aspirin" asthma;
• peptic ulcer of the stomach and duodenum in the phase of exacerbation;
• Gastrointestinal, cerebrovascular or other bleeding;
• severe renal failure (if hemodialysis is not performed);
• severe hepatic impairment;
• severe heart failure;
• children's age till 15 years;
• pregnancy;
• lactation period (breastfeeding);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Bi-xikam is contraindicated in pregnancy.

If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.

In experimental studies, there was no teratogenic effect of meloxicam.

Use in children

Contraindicated in childhood to 15 years.

Application in elderly patients

With caution and under the control of renal function indicators, the drug should be used in elderly patients.

With caution should be used in elderly patients, with erosive and ulcerative lesions of the gastrointestinal tract in the anamnesis.

special instructions

It should be used with caution in patients with a history of gastric ulcer and duodenal ulcer, as well as in patients receiving anticoagulant therapy. In such patients, the risk of erosive and ulcerative gastrointestinal lesions is increased.

With caution and under the control of renal function indicators, the drug should be used in elderly patients, patients with chronic heart failure with circulatory failure, in patients with cirrhosis, as well as in patients with hypovolemia as a result of surgical interventions.

In renal failure, if creatinine clearance (CK) is more than 25 ml per minute, correction of the dosing regimen is not required.

In patients on dialysis, the maximum dose of the drug is 7.5 mg per day.

Patients taking both diuretics and meloxicam should receive a sufficient amount of fluid.

If allergic reactions (including pruritus, skin rash, urticaria) occur during the treatment, as well as photosensitization, the patient should consult a doctor to resolve the issue of discontinuing the drug.

Impact on the ability to drive vehicles and manage mechanisms

The use of the drug can cause the occurrence of undesirable effects in the form of headaches and dizziness, drowsiness. If the above phenomena occur, it is necessary to abandon the management of vehicles, maintenance of machinery and mechanisms.

Drug Interactions

With the simultaneous use of B-ksikam with other NSAIDs (as well as with acetylsalicylic acid), the risk of erosive-ulcerative lesions and bleeding from the gastrointestinal tract increases.

With simultaneous use with antihypertensive drugs, it is possible to reduce the effectiveness of the latter.

With simultaneous use with lithium preparations, development of cumulation of lithium and increase of its toxic effect (it is recommended to control the concentration of lithium in the blood).

With simultaneous use with methotrexate, the side effect of the latter on the hematopoietic system is increased (the risk of anemia and leukopenia, periodic monitoring of the general blood test is shown).

With simultaneous use with diuretics and with cyclosporine, the side effects of the latter increase with the possibility of developing renal failure.

With simultaneous use with intrauterine contraceptives, the effectiveness of the latter may be reduced.

When used simultaneously with anticoagulants (including heparin, ticlopidine, warfarin), as well as with thrombolytic drugs (streptokinase, fibrinolysin), the risk of bleeding increases (periodic monitoring of blood clotting indices is necessary).

With the simultaneous use of Bixikam with colestyramine, as a result of binding meloxicam, its excretion through the digestive tract increases.

Analogues of the drug Bi-xikam

Structural analogs for the active substance:

• Amelotex;
• Arthrosan;
• Genitron;
• Lem;
• Liberalum;
• Matarin;
• Medsikam;
• Melbeck;
• Melokvitis;
• Meloks;
• Meloksam;
• Meloksikam;
• Meloflam;
• Meloflex;
• Mesipol;
• Mixol-Od;
• Mirlocks;
• Movalis;
• Movasin;
• Movix;
• Oxycamox;
• Flexibon;
• Exen-Sanovel.

Analogues of the preparation Bi-ksikam on the pharmacological group (NSAIDs - oxicams):

• Amelotex;
• Artoxane;
• Arthrosan;
• Genitron;
• Zornika;
• Kalmopyrene;
• Xsefokam;
• Lem;
• Liberalum;
• Lornoxicam;
• Matarin;
• Medsikam;
• Melbeck;
• Melbek forte;
• Melokvitis;
• Meloksam;
• Meloksikam;
• Meloks;
• Meloflam;
• Meloflex;
• Mesipol;
• Mixol-Od;
• Mirlocks;
• Movalis;
• Movasin;
• Movix;
• Oxycamox;
• Pirokam;
• Piroxicam;
• Piroximeter;
• Revmadore;
• Remoxicam;
• Sanik;
• Texared;
• Tenikam;
• Tenoktil;
• Teraflex;
• Tilcotyl;
• Tobitil;
• Feldoral;
• Velden;
• Finalal;
• Flexibon;
• Chondroxide;
• Hotemin;
• Exen.

Response of a rheumatologist

I prescribe Bixikam in my practice to patients with degenerative and inflammatory diseases of joints, especially if the clinical picture is dominated by pain syndrome.The medicine is good and fast enough, even if the patient takes it in the form of tablets, relieves pain and swelling in the joints. With pronounced symptoms of inflammation I prescribe intramuscular injections of B-ksikam. Unwanted reactions to drug treatment are, but not often. There were cases of skin rashes, increased pressure, dizziness, noise in the ears.

Similar medicines:

Other medicines: